Indication: Dosage & Administration:
as well as panic disorder, with or without agoraphobia. Epilepsy and
other seizure disorders. Alone or as an adjunct in the management of
myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut
syndrome). May also be of some value in patients with absence spells
(petit mal) who have failed to respond to succinimides.
Dosage must be determined in each patient according to clinical response and tolerance.
The initial dose for infants and children (up to 10 years of age or 30
kg of body weight) should be between 0.01 and 0.03 mg/kg/day and should
not exceed 0.05 mg/kg/day given in two or three divided doses. Dosage
should be increased by not more than 0.25 to 0.50 mg every third day
until a maintenance dose of 0.1 to 0.2 mg/kg of body weight has been
reached, unless seizures are controlled or side effects preclude further
increase. Whenever possible, the daily dose should be divided into
three equal doses. If doses are not equally divided, the larger dose
should be given before retiring.
Adults :1 mg (elderly 500
micrograms) initially at night for 4 nights, increased according to
response over 2-4 weeks to usual maintenance dose of 4-8 mg usually at
night (may be given in 3-4 divided doses if necessary). Dosage may be
increased in increments of 0.5 to 1 mg every three days until seizures
are adequately controlled.